Best innovative pharmaceuticals firm, 2020..SophiaSmeeth
India plays a pivotal role in the global pharmaceuticals Industry by being one of the largest providers of generic drugs globally. Innovation and low costs of manufacturing are some of the clear advantages that India offers in the global space. The Pharma industry has grown exponentially over the last few years. Here we are going to feature the "Best Innovative Pharmaceuticals Firm_ 2020" that playing the best roll in Pharmaceuticals industry.
Best innovative pharmaceuticals firm, 2020..SophiaSmeeth
India plays a pivotal role in the global pharmaceuticals Industry by being one of the largest providers of generic drugs globally. Innovation and low costs of manufacturing are some of the clear advantages that India offers in the global space. The Pharma industry has grown exponentially over the last few years. Here we are going to feature the "Best Innovative Pharmaceuticals Firm_ 2020" that playing the best roll in Pharmaceuticals industry.
This is a basic report of BEXIMCO pharma industry. Only basic tools and topics of management were used to prepare this report. This report might help the students who are doing MGT 210 COURSE in North South University of BANGLADESH.
an assignment on business level strategies and its impact on the performance of an industrial company in bangladesh: a case study on square pharmaceuticals limited
This report is based on the summer training undertaken with lupin ltd anleshwar. It will be beneficial to the students who appear for training with lupin ankleshwar. The report also contains mini project on job rotation and transfer.
Research Report on Abbott India Ltd. on the basis of Company Profile, Management, Shareholding Pattern, SWOT Analysis, Competitive Analysis, and Way forward.
To recap the previous month's pharma highlights to Pharma Uptoday members, Monthly magazine Volume 6 has been released with
News Uptoday
New Guidance
New MAPP Release
Audit Findings
483 Observations
- 483 of Impax Laboratories
- 483 of Ipca Labs
- 483 of Bausch & Lomb Inc
- 483 of Alexion
Warning Letters
- Marck Biosciences Ltd.
- The Compounding Shop Inc.
- Zions Rx Formulations Services LLC.
EMA Non-Compliance Reports
- Renown Pharmaceuticals Pvt. Ltd., India
- VETPROM AD, Bulgaria
- SCM PHARMA LIMITED, UK
Guest of the Month
Dr. M Damodharan - Vice President Global Quality & Regulatory
Regulations of the Month
§ 211.180 Subpart J--Records and Reports - General Requirements
§ 211.182 Subpart J--Records and Reports - Equipment cleaning & use log
This is a basic report of BEXIMCO pharma industry. Only basic tools and topics of management were used to prepare this report. This report might help the students who are doing MGT 210 COURSE in North South University of BANGLADESH.
an assignment on business level strategies and its impact on the performance of an industrial company in bangladesh: a case study on square pharmaceuticals limited
This report is based on the summer training undertaken with lupin ltd anleshwar. It will be beneficial to the students who appear for training with lupin ankleshwar. The report also contains mini project on job rotation and transfer.
Research Report on Abbott India Ltd. on the basis of Company Profile, Management, Shareholding Pattern, SWOT Analysis, Competitive Analysis, and Way forward.
To recap the previous month's pharma highlights to Pharma Uptoday members, Monthly magazine Volume 6 has been released with
News Uptoday
New Guidance
New MAPP Release
Audit Findings
483 Observations
- 483 of Impax Laboratories
- 483 of Ipca Labs
- 483 of Bausch & Lomb Inc
- 483 of Alexion
Warning Letters
- Marck Biosciences Ltd.
- The Compounding Shop Inc.
- Zions Rx Formulations Services LLC.
EMA Non-Compliance Reports
- Renown Pharmaceuticals Pvt. Ltd., India
- VETPROM AD, Bulgaria
- SCM PHARMA LIMITED, UK
Guest of the Month
Dr. M Damodharan - Vice President Global Quality & Regulatory
Regulations of the Month
§ 211.180 Subpart J--Records and Reports - General Requirements
§ 211.182 Subpart J--Records and Reports - Equipment cleaning & use log
LASA LABS has worked on developing unique manufacturing processes with a focus on low cost of production. A competent team is working on customer service and satisfaction. Hence the product will be highly competitive and cost effective for international markets.
Disorders of kidney and urinary tract are commonly seen in pediatric units as medical and surgical problems. Congenital malformations, neoplasms, infections, inflammations and progressive impairment of renal functions are common conditions found in children.
Hemorrhage is a process of lose of blood either through a wound or because of any medical condition. Children are very prone to injuries as they are in the stage of attaining their motor developments.
metabolic acidosis develops because of defects in the ability of the renal tubules to perform the normal functions required to maintain acid-base balance.
Different medications must be absorbed to be effective. For absorption, the drug must be administered in proper manner. To choose a route of administration we need to relate the dosage form, the advantages and disadvantages etc.
Pharmaceutical, Bulk Drugs and Medicine Manufacturing Industry (Production, F...Ajjay Kumar Gupta
Quality control and quality assurance are vital in this industry. Many production workers are assigned full time to quality control and quality assurance functions, whereas other employees may devote part of their time to these functions. For example, although pharmaceutical company sales representatives, often called detailers, work primarily in marketing, they engage in quality control when they assist pharmacists in checking for outdated products.
Advances in manufacturing processes are also impacting the industry. While pharmaceutical manufacturers have long devoted resources to new drug development as a source for future profits, firms are increasingly realizing that improvements throughout the drug pipeline are needed to stay competitive.
See more
http://goo.gl/1sQLwS
http://goo.gl/jajeNa
http://goo.gl/0tvlst
http://www.entrepreneurindia.co/
Tags
Pharmaceutical Technology Books, Essentials of Pharmaceutical Technology, Pharmaceutical Technology, Pharmaceutical books, Science, Technology & Medicine Books, Drugs technology books, Drug and Pharmaceuticals technology book, Best small and cottage scale industries, Bulk Drugs Formulation, Bulk Drugs Manufacturing Industry, Business consultancy, Business consultant, Business guidance for Pharmaceutical industry, Business guidance to clients, Business Plan for a Startup Business, Creating a Pharma Start-up, Drug formulation manual, Formulation of Antibiotics, Formulation of Paracetamol, Formulation of Tablets, Great Opportunity for Startup, How to Start a Medicines manufacturing business?, How to start a pharmaceutical company, How to Start a Pharmaceutical Product Business, How to Start a Pharmaceutical Production Business, How to start a pharmacy business, How to start a successful drugs making business, How to start Antibiotics manufacturing business, How to start drugs pharmaceutical business, How to start medicine business, How to Start Medicine Manufacturing Industry in India, How to start medicine manufacturing, How to start Paracetamol production business, How to Start Pharmaceutical Manufacturing Company in India, Invest to setup a pharmaceutical business, Manufacturing of medicinal products- Pharmaceutical industry, Medicine Manufacturing Industry, Medicines Making Small Business Manufacturing, Modern small and cottage scale industries, Most Profitable Bulk Drugs production Business Ideas, New small scale ideas in Pharmaceutical industry, Pharma Manufacturing, Pharmaceutical and Medicines production Business, Pharmaceutical Based Profitable Projects, Pharmaceutical Based Small Scale Industries Projects, Pharmaceutical Drug Formulation, Pharmaceutical Drug Manufacturing Business, Pharmaceutical formulation guidelines, Pharmaceutical formulation, Pharmaceutical industry in India, Pharmaceutical industry, Pharmaceutical manufacturing Industry in India, Pharmaceutical Manufacturing Industry, Pharmaceutical Projects,
0601017 explore market opportunities for new product launchSupa Buoy
Hi Friends
This is supa bouy
I am a mentor, Friend for all Management Aspirants, Any query related to anything in Management, Do write me @ supabuoy@gmail.com.
I will try to assist the best way I can.
Cheers to lyf…!!!
Supa Bouy
We offer PCD Pharma Franchise all over India at very low investment initially and dealing in all Pharma Products Categories. We are serving as one of the Best Pharma Franchise Company in India.
Opportunities of BDS in Pharmaceutical Industries.pptxDr. Manoj Kumbhare
India is the second-largest pharmaceutical market in Asia. ... A BDS graduate can have various job roles available in this sector: Principal Investigator, Co-investigator, Medical Advisor, Drug Developer, Regulatory Affairs Manager or even a Clinical Research Physician.
Career opportunities in the clinical research field are many and varied, with employment settings ranging from pharmaceutical and biotechnology, to medical device companies, contract research organizations, hospitals, educational institutions, independent contractors and more.
Many professionals with a strong science or healthcare related background — such as nurses, pharmacists, medical technologists, physicians and more — are well-positioned to join the clinical research field. Here are 10 career paths in the field.
0601017 explore market opportunities for new product launchSupa Buoy
Hi Friends
This is supa bouy
I am a mentor, Friend for all Management Aspirants, Any query related to anything in Management, Do write me @ supabuoy@gmail.com.
I will try to assist the best way I can.
Cheers to lyf…!!!
Supa Bouy
Trends, recruitment and remuneration in the Healthcare & Life Sciences sectorMichael Page
This report arises out of Michael Page’s global experience in helping companies in the Healthcare & Life Sciences sector to recruit the best talents for business success. In most of the countries where we operate, the prevailing regulatory and pricing frameworks set by government heavily influence the market. Now that many patents have reached end of life, generic drugs have taken an important share from large pharmaceuticals, and have revolutionised the market in doing so. As a consequence, companies producing pharmaceuticals or medical devices are increasingly challenged to hone their profitability through innovation and R&D. Acquisitions, always a feature of the pharmaceutical industry, are on the increase. Many companies needing to expand their R&D capabilities have biotechnology firms in their sights.
3 News Uptoday
22 New Guidance
28 Audit Findings
483 Observations
- Caraco Pharmaceutical Laboratories
- Hospira Inc
- Novartis Consumer Health
- McNeil Consumer Healthcare
Warning Letters
- Hikma Farmaceutica, (Portugal) S.A.
- Cadila Pharmaceuticals Limited
- Sharp Global Limited
- Wells Pharmacy Network LLC
EMA Non-Compliance Reports
- Taishan City Chemical Pharmaceutical Co. Ltd., China
- Zhejiang Apeloa Kangyu Bio-Pharmaceutical Co. Ltd., China
- MANUEL RIESGO S.A., Spain
- Ranbaxy Laboratories Limited, Dewas, India
36 Regulations of the Month
§ 211.186 Master production and control records
§ 211.188 Batch production and control records
The Unethical Practices of the Pharmaceutical Industries in Bangladesh in the...Dr. Amarjeet Singh
This article highlights the unethical practices of pharmaceutical industries in Bangladesh in their drug promotion and its impacts. It is evident that pharmaceutical industry is one of the promising sectors in the industrial field of Bangladesh. Now, the pharmaceutical industries of Bangladesh are exporting their products to more than 100 countries in the world after meeting the local demand. This study also represents the growth and market share of pharmaceutical industries, total exports of last five years, unethical practices in promotion of pharmaceutical industries and impacts of unethical practices. To conduct the study both secondary and primary data have been used. The target population of this study was medical professional men including physicians of Phultala Thana in Khulna District. Finally the study provides some recommendations to overcome the situation. There are a lot of rooms for Bangladesh to develop in this sector. In this study, the unethical practices in promotion of pharmaceutical industries that can make obstacle in the sustainable growth of pharmaceutical business in Bangladesh are discussed meticulously.
Top mailing list providers in the USA.pptxJeremyPeirce1
Discover the top mailing list providers in the USA, offering targeted lists, segmentation, and analytics to optimize your marketing campaigns and drive engagement.
Personal Brand Statement:
As an Army veteran dedicated to lifelong learning, I bring a disciplined, strategic mindset to my pursuits. I am constantly expanding my knowledge to innovate and lead effectively. My journey is driven by a commitment to excellence, and to make a meaningful impact in the world.
Navigating the world of forex trading can be challenging, especially for beginners. To help you make an informed decision, we have comprehensively compared the best forex brokers in India for 2024. This article, reviewed by Top Forex Brokers Review, will cover featured award winners, the best forex brokers, featured offers, the best copy trading platforms, the best forex brokers for beginners, the best MetaTrader brokers, and recently updated reviews. We will focus on FP Markets, Black Bull, EightCap, IC Markets, and Octa.
Anny Serafina Love - Letter of Recommendation by Kellen Harkins, MS.AnnySerafinaLove
This letter, written by Kellen Harkins, Course Director at Full Sail University, commends Anny Love's exemplary performance in the Video Sharing Platforms class. It highlights her dedication, willingness to challenge herself, and exceptional skills in production, editing, and marketing across various video platforms like YouTube, TikTok, and Instagram.
At Techbox Square, in Singapore, we're not just creative web designers and developers, we're the driving force behind your brand identity. Contact us today.
Recruiting in the Digital Age: A Social Media MasterclassLuanWise
In this masterclass, presented at the Global HR Summit on 5th June 2024, Luan Wise explored the essential features of social media platforms that support talent acquisition, including LinkedIn, Facebook, Instagram, X (formerly Twitter) and TikTok.
The 10 Most Influential Leaders Guiding Corporate Evolution, 2024.pdfthesiliconleaders
In the recent edition, The 10 Most Influential Leaders Guiding Corporate Evolution, 2024, The Silicon Leaders magazine gladly features Dejan Štancer, President of the Global Chamber of Business Leaders (GCBL), along with other leaders.
Implicitly or explicitly all competing businesses employ a strategy to select a mix
of marketing resources. Formulating such competitive strategies fundamentally
involves recognizing relationships between elements of the marketing mix (e.g.,
price and product quality), as well as assessing competitive and market conditions
(i.e., industry structure in the language of economics).
In the Adani-Hindenburg case, what is SEBI investigating.pptxAdani case
Adani SEBI investigation revealed that the latter had sought information from five foreign jurisdictions concerning the holdings of the firm’s foreign portfolio investors (FPIs) in relation to the alleged violations of the MPS Regulations. Nevertheless, the economic interest of the twelve FPIs based in tax haven jurisdictions still needs to be determined. The Adani Group firms classed these FPIs as public shareholders. According to Hindenburg, FPIs were used to get around regulatory standards.
Understanding User Needs and Satisfying ThemAggregage
https://www.productmanagementtoday.com/frs/26903918/understanding-user-needs-and-satisfying-them
We know we want to create products which our customers find to be valuable. Whether we label it as customer-centric or product-led depends on how long we've been doing product management. There are three challenges we face when doing this. The obvious challenge is figuring out what our users need; the non-obvious challenges are in creating a shared understanding of those needs and in sensing if what we're doing is meeting those needs.
In this webinar, we won't focus on the research methods for discovering user-needs. We will focus on synthesis of the needs we discover, communication and alignment tools, and how we operationalize addressing those needs.
Industry expert Scott Sehlhorst will:
• Introduce a taxonomy for user goals with real world examples
• Present the Onion Diagram, a tool for contextualizing task-level goals
• Illustrate how customer journey maps capture activity-level and task-level goals
• Demonstrate the best approach to selection and prioritization of user-goals to address
• Highlight the crucial benchmarks, observable changes, in ensuring fulfillment of customer needs
Agency Managed Advisory Board As a Solution To Career Path Defining Business ...
Pharma news
1. Pharmaceuticals
Chemical Weekly April 17, 2012146
INVESTING IN RESEARCH
Biocon opens biologics research centre in Bangalore
Biocon has opened an in-
tegrated R&D centre in Ban-
galore, which will pursue re-
search on biologics to address
unmet medical needs. Bio-
logics is the science of mak-
ing medicinal products from
living organisms. The Rs.
200-crore Biocon Research
Centre (BRC) is a first of its kind fa-
cility in South-east Asia, the company
said. The research centre is equipped
with multi-disciplinary capabilities in
molecular biology, biologics process
sciences, formulation research and
preclinical & clinical development.
The centre is also equipped with in-
strumentation for extensive molecular
and functional characteri-
sation of biologics. Biocon
will hire about 300 scien-
tists within the next one
year at the research centre.
An equal number of scien-
tists already work in the re-
search facility, which was
formally opened by Prof.
Kurt Wuthrich, who won the Nobel
Prize for chemistry in 2002. Speaking
at the occasion, Ms. Kiran Mazumdar-
Shaw, Chairman and Managing Di-
rector, Biocon Group said, “We plan
to pursue an innovation-led effort to
develop advanced yet affordable solu-
tions for several debilitating diseases
through this research centre.” She said
the company would pursue the goal
of developing affordable medicines in
the focus areas of diabetes, cancer and
autoimmune diseases.
Good prospects in biosimilars
Prof. Wuthrich said biotech is the
future for top quality drug develop-
ment. “This is where innovative medi-
cines will play a pivotal role. Develop-
ment of biosimilars is being viewed as
future growth path for pharma and bio-
tech companies globally,” he said. “The
scene for development of biosimilars
is not easy like the small molecule, but
there is considerable science and tech-
nology which gives advantage for the
development of biosimilars,” he added.
CUSTOMER-CENTRIC APPROACH
‘Pharma companies need to reinvent business models
to be patient-centric’
With chronic diseases now account-
ing for three quarters of all healthcare
spending in developed countries, life
sciences companies will face increas-
ing pressure to demonstrate that they
are helping patients adopt healthier
behaviour and manage their diseases
more effectively. Pharma and health-
care companies will be required to
fundamentally reinvent their business
models to make them more patient-
centric and better able to drive beha-
vioural changes in consumers, accord-
ing to Ernst & Young’s latest annual
report “Progressions 2012 - The third
place: health care everywhere”.
To bring down costs and improve
health outcomes, patients and stake-
holders of the healthcare system need
to change their behaviour. And for this,
the epicentre of healthcare – how it is
produced, dispensed and consumed and
paid for – will move beyond the two
traditional places it has been delivered,
to where the patient is, the report said.
E&Y said with an increasing
chronic disease burden and poor
health indicators in India, there is a
pressing need to influence patient be-
haviours to improve health outcomes.
India is the world’s diabetes capital
with 61.3-mn diabetics in 2011 and
projected to reach 101.2-mn by 2030.
Coronary heart disease prevalence is
projected to increase from 36-mn in
2005 to 62-mn by 2015. The new im-
perative for life sciences companies
to better understand patient behaviour
and influence positive changes is be-
ing accelerated by two key trends, it
said. Given that India is amongst the
world’s fastest-growing “internet na-
tions,” with more than 100-mn internet
subscribers and a smartphone market
to cross 80-mn units per year by 2015,
this would be an important enabler to
improve accessibility of healthcare to
a large population in the country there-
by making healthcare ubiquitous.
Mr. Hitesh Sharma, Partner & Na-
tional Leader – Life Sciences, E&Y
said, “Almost every life sciences com-
pany, regardless of their product or of-
fering, will soon be expected to help
change behaviours and deliver better
health outcomes.” In the Indian con-
text, while technology based patient
behaviour would yield good results for
companies investing in these areas, it
could also be interesting to see if a Pub-
lic Private Partnership model would be
considered by the government to enable
reach to the large Below Poverty Line
population from an educational/pre-
vention perspective using behavioural
analytics, Mr. Sharma said.
2. Pharmaceuticals
Chemical Weekly April 17, 2012148
FORWARD INTEGRATION
Omkar Speciality enters API business with acquisition
of Lasa Laboratory
Rs. 15-crore in upgrading the facil-
ity and expanding capacities from
the existing levels of about 100-tpa
to 400-tpa. The upgraded facilities
would conform to WHO-GMP norms,
enabling enhanced exports to overseas
markets.
“Our new API division is already
in operations and will initially focus
on continuing the existing API busi-
ness of Lasa Lab, which has massive
demand in India and abroad,” in-
formed Mr. Herlekar. “Currently, our
product portfolio comprises 10 pro-
ducts in the veterinary/anthelmintics
segment, mainly benzimidazoles and
other APIs. This acquisition is strate-
gic for the company in terms of open-
ing up new verticals, as well as value
addition. Now we can convert some of
the intermediates that we manufacture
into final APIs. We have a market for
that, but unfortunately we never had
any API facility for launching these
products. So this is an opportunity
for us to go ahead with that plan,” he
added.
used as anthelmintics/
deworming agents for
the veterinary sector.
Speaking at a
press conference in
Mumbai, Mr. Pravin
Herlekar, Chairman
& Managing Direc-
tor, Omkar Speciality
said, “There is a co-
lossal demand in the
API manufacturing
space, and with Indian drug manu-
facturing sector gaining international
prominence, the acquisition of Lasa
Laboratory was the right move for our
group to venture into the pharma busi-
ness. It is also a part of our group’s for-
ward integration strategy.”
Mr. Herlekar informed that the ac-
quisition price was around Rs. 6-crore.
He said the manufacturing facility of
Lasa Lab had begun operations only a
few months ago and the company had
a turnover of close to Rs. 2-crore. Om-
kar Speciality plans to invest around
Omkar Speciality
Chemicals Ltd, a leading
manufacturer of specia-
lity chemicals, has entered
the active pharmaceutical
ingredient (API) business
with the acquisition of
Lasa Laboratory P. Ltd. lo-
cated at Mahad in Raigad
district. Lasa Laboratory
is an established player
in the anthelmintic/veteri-
nary API segment.
Omkar Speciality is involved in
manufacturing speciality chemicals
like derivatives of selenium, iodine,
molybdenum, cobalt and bismuth as
well as pharma intermediates. The
acquisition will enable the company
to move from manufacturing interme-
diates for pharma industry to manu-
facturing APIs like albendazole EP,
albendazole IP/USP, cyromazine,
fenbendazole BP vet / EP, nitroxynil
BP vet, ricobendazole, toldimphos
sodium and triclabendazole, company
press note informed. The products are
NEW DRUG R&D
Aanjaneya Lifecare debuts new fiscal with three
global recognitions
Mumbai-based Aanjaneya Lifecare
Ltd., a leading manufacturer of bulk
drugs, has bagged three awards at the
beginning of the new fiscal.
The company has been awarded the
Certificate of Merit in Small Business
Category of IMC Ramakrishna Bajaj
Award 2012, one of the most prestigious
quality awards in India; and an award
for ‘Best Corporate Governance,’ at the
3rd Annual India Leadership Conclave
& Business Awards 2012.
In addition, its Vice Chairman &
Managing Director, Dr. Kannan Vish-
wanath won the ‘Business Leader of
The Year’ award, for spearheading
the strategic shift of Aanjaneya Life-
care from standalone API company to
an integrated pharma company with
global aspirations. He was also recog-
nized for his leadership skills, which
made Aanjaneya Lifecare the world’s
third largest manufacturer of quinine
salts with a global footprint across 40
countries.
3. Pharmaceuticals
149Chemical Weekly April 17, 2012
FUTURE OUTLOOK
‘India nutraceutical market to grow to $2.73-bn in 2016’
The nutraceutical market in India is
estimated to grow to $2.73-bn in 2016
at a CAGR of 13% driven mainly by
increasing disposable income and stan-
dards of living, aggressive retail market-
ing, urbanisation of the mass population
and increased awareness of functional
benefits. Functional foods will be the
quickest growing category till 2015, fol-
lowed by dietary supplements. However,
dietary supplements, specifically herbal
and dietetic supplements, will form the
greatest opportunity areas for nutraceu-
tical manufacturers, driven by growing
demand from an evolving consumer
base, states a new report jointly released
by Frost & Sullivan and the 7th Nutra
India Summit Conference Secretariat.
The Indian nutraceutical market is domi-
nated by pharmaceutical and fast-mov-
ing consumer goods (FMCG) giants.
While dietary supplements, such as vita-
min and mineral supplements, have been
captured by pharmaceutical companies,
functional food and beverages are now
being brought to the market by FMCG
companies. However, certain segments
like dietetic supplements, are now be-
ing catered to by pure-play nutraceutical
companies, apart from their pharmaceu-
tical and FMCG counterparts.
“The Indian nutraceutical market
was valued at $1.48-bn in 2011. Dietary
supplements were the largest category
accounting for 64% of the market,
driven primarily by the pharmaceutical
sector in the form of vitamin and mine-
ral supplements,” the report revealed.
“Functional foods (24%) and function-
al beverages (12%) are relatively na-
scent markets in India, primarily due to
the existence and reliance on traditional
wisdom and Ayurveda by a burgeoning
middle class, which accounts for a huge
chunk of the purchasing power in India.
Further, the marketing of products such
as sports and energy drinks, is primarily
targeted at niche segments of the urban
population, resulting in low penetration
for these products, even amongst the
urban population. Growth of the dietary
supplements will be spurred forward by
the growing demand for dietetic sup-
plements, due to an urban, fitness con-
scious, young population,” informed
Mr. Raghavendra Rao, Vice President,
South Asia & Middle East, Chemicals,
Materials and Foods, Frost & Sullivan.
Global scenario
The global nutraceutical market in
2011 was estimated to be $149.5-bn,
with US, Europe and Japan being the
largest regional markets accounting
for nearly 93% of the global demand.
These markets are nearing maturing,
with exceedingly high per capita spends
on nutraceuticals products; while Japan
has a per capita spend of $51/person/
year, US and Europe have $40 and $35
each, and the global average is only
around $21/person/year. This is forcing
nutraceutical manufacturers to look at
developing countries, such as India and
China, which have considerably lower
per capita spends on nutraceutical pro-
ducts, as key growth regions.
DISTRIBUTION ARRANGEMENT
Probi signs agreement with USV for probiotics
Sweden-based, Probi,
a leading player in the pro-
biotic research and the de-
velopment of efficient and
well-documented probio-
tics, has signed a distribu-
tion agreement with USV
Ltd., a leading Pharmaceu-
tical company. USV will
launch Vibact IBS based
on the probiotic formula-
tion Probi Digestis, in Q4 2012 in the
growing Indian market. The agreement
reinforces and strengthens Probi’s ex-
isting presence in the large Indian mar-
ket. “USV is the best probiotic partner
in the consumer healthcare sector in
India. We are very pleased to
partner with USV and to be
able to launch our probiotic
formulation Probi Digestis
in a market with significant
growth potential,” says Mr.
Michael Oredsson, CEO
of Probi. Probi’s capsules
based on the Lactobacillus
plantarum 299v strain will
be launched under the Vi-
bact IBS brand and will feature Probi’s
logo and ingredient prominently on the
pack. USV offers a market leading pro-
biotic prescription brand, Vibact, in
India. Vibact IBS will specifically target
IBS symptoms like bloating, flatulence
and pain. These are symptoms, which
are common in the Indian population.
USV will use its extensive field force to
market the product across India.
“Probi’s well-documented and ef-
fective IBS probiotic will be a unique
addition to our range and will strength-
en our market position. We are certain
that the product will be well received in
the market,” says Mr. Prashant Tewari,
Managing Director at USV. Probi’s
partner Institut Rosell’s current distri-
bution agreements in India covering
Lp299v capsules with Aristo Pharma-
ceuticals and Ranbaxy will remain in
force, but limited overlap is expected.
Mr. Prashant Tewari
4. Pharmaceuticals
151Chemical Weekly April 17, 2012
HELPING HAND
Special fund mooted to assist SMEs comply with
exacting standards of regulated markets
If a proposal of the Department of
Pharmaceuticals (DoP) gets through, as
many as 250 select small and medium
scale pharma companies will get spe-
cial assistance to develop international
competitiveness by upgrading to the
standards of highly regulated markets.
The scheme, which aims to special-
ly equip the companies to adopt inter-
national standards higher than WHO-
GMP, envisages Rs. 2 crore each to 250
select units. The DoP is said to have
submitted the proposal to the Planning
Commission for approval.
The aim of the scheme is to extend
special assistance to build competitive-
ness of very high standards and ‘second
line of internationally capable indus-
try for high value pharma products for
strong regulated but high value mar-
kets.’ It will help them upgrade manu-
facturing facilities, including in the bio-
pharma sector, to US Food and Drug
Administration (US FDA), European
Directorate for the Quality of Medi-
cines (EDQM), Therapeutic Goods
Administration (TGA) of Australia and
other international standards to enable
global generic and biosimilar capabili-
ties.
“The export of pharmaceutical
products constitutes nearly 45% of
turnover of Indian pharma industry.
In view of the growing importance of
generic medicines and the advent of
biosimilars in high regulated world
market, Indian pharma manufacturers
need to build capacity for compliance
to the stringent standards of high regu-
lated yet high value market countries
– US, West EU, Australia and South
Africa. Therefore, it is proposed that
250 select units be provided assistance
by 2017 to upgrade their facilities as
per the requirement of these countries
and other international standards,” the
proposal said.
NEWS IN BRIEF
Suven Life gets four
product patents for
NCEs
Hyderabad-based Suven Life
Sciences has obtained four product
patents, two each from China and
Korea. These correspond to the new
chemical entities (NCEs) for the
treatment of disorders connected
to the brain functions. The patents
would be valid through 2025 and
2027, the company said in a press
note. With these patents, Suven has
a total of five granted patents from
China and seven from Korea. The
company is developing therapeutic
agents, which would be useful in the
treatment of diseases like Alzhei-
mer’s, Parkinsons, Schizophrenia
and attention deficient hyperactivity
disorder, the release said.
DIAGNoSTIC KIT
DRDO launches India’s first swine flu detection kit
Dr. Vijay Kumar
Saraswat, scientific advi-
sor to Defence recently
launched a kit developed
by Defence Research &
Development Organiza-
tion (DRDO) to detect
Swine Flu (H1N1) virus.
The detection kit
is being manufactured by RAS Life-
sciences, Hyderabad, following a
licensing agreement with DRDO
for transfer of technology under the
DRDO-Federation of Indian Chambers
of Commerce and Industry (FICCI)
Accelerated Technology
Assessment & Commer-
cialization (ATAC) pro-
gramme.
The DRDO-FICCI
ATAC programme is an
initiative of DRDO and
FICCI that aims for com-
mercialisation of tech-
nologies developed by various labs of
DRDO for civilian applications. Within
a short span of 18 months, more than
25 DRDO technologies have been suc-
cessfully commercialised under this
programme.
Defence Research Development
Establishment (DRDE), Gwalior, a con-
stituent laboratory under DRDO had
developed the diagnostic kit that can
detect H1N1 virus in an hour. The kit
does not need sophisticated instruments
and can be used in villages where elec-
tricity is not available. It uses a simple
technique called real-time loop ampli-
fication methodology (RT LAMP) to
detect the virus. The assay is based on
a simple isothermal gene amplification
principle, using a specially designed
primer that specifically amplify the H1
(hemagglutinin) gene of H1N1 virus
only.